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Preconditioning with death ligands FasL and TNF-alpha protects
the cirrhotic mouse liver against ischaemic injury
Abstract
BACKGROUND: Ischaemic preconditioning is the preemptive proven strategy to reduce ischaemic
injury in the liver, but it can be harmful in the elderly or in patients with liver diseases. Ischaemic
preconditioning induces a protective effect via activation of oxidative stress. We hypothesised that Fas
ligand and tumour necrosis factor alpha can induce a similar response. Therefore, we tested if death
ligands could mimic ischaemic preconditioning. METHODS: Ischaemia was maintained for 60 min in
cirrhotic mice. Death ligands were given 40 min before ischaemia. Ischaemic injury was assessed by
histology and biochemical assays. To elucidate the mechanism, we used zinc protophorphyrin, an
inhibitor of haem oxygenase-1 (HO-1), and gadolinium chloride, an inhibitor of Kupffer cells.
RESULTS: Compared with the control group, death ligand preconditioning strongly reduced all markers
of injury: serum transaminase levels, necrosis and apoptosis. Preconditioning caused an upregulation of
HO-1, predominantly in macrophages. When zinc protophorphyrin or gadolinium chloride was applied
prior to preconditioning, the beneficial effect of preconditioning was lost. CONCLUSION: These results
demonstrate that ischaemic preconditioning can be replaced by death ligand preconditioning in the
cirrhotic liver to prevent ischaemic injury. The protective mechanism depends on HO-1 induction in
macrophages. These results open doors for novel hepato-protective strategies in liver surgery and
transplantation.
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Abstract  
Background: Ischemic preconditioning is the pre-emptive proven strategy to reduce 
ischemic injury in the liver, but it can be harmful in the elderly or patients with liver 
diseases. Ischemic preconditioning induces protective effect via activation of oxidative 
stress. We hypothesized that Fas ligand and tumor necrosis factor can induce a similar 
response. Therefore, we tested if death ligands could mimic ischemic preconditioning. 
Ischemia was performed for 60 minutes in cirrhotic mice.  
Methods: Death ligands were given 40 minutes before ischemia. Ischemic injury was 
assessed by histology, and biochemical assays. To elucidate the mechanism, we used 
zinc- protophorphyrin, an inhibitor of heme oxygenase-1 and gadolinium chloride, an 
inhibitor of Kupffer cells.  
Results: Compared to the control group, death ligand preconditioning strongly reduced 
all markers of injury: serum transaminase levels, necrosis and apoptosis. 
Preconditioning caused an up-regulation of heme oxygenase-1, predominantly in 
macrophages. When zinc-protophorphyrin or gadolinium chloride was applied prior to 
preconditioning, the beneficial effect of preconditioning was lost. 
Conclusion: These results demonstrate that ischemic preconditioning can be replaced by 
death ligand preconditioning in the cirrhotic liver to prevent ischemic injury. The 
protective mechanism is depending on heme oxygenase-1 induction in macrophages. 
These results open doors for novel hepato-protective strategies in liver surgery and trans
plantation. 
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Introduction 
Hepatocellular carcinoma arising in patients with underlying cirrhosis is the fourth most 
common cause of death from cancer 1 with a rising incidence worldwide owing to the 
increasing prevalence of viral hepatitis, as well as non alcoholic steatohepatitis 2 3. 
Transplantation can be offered to very few patients, and therefore liver resection 
remains the sole option for cure in many patients 4. The presence of cirrhosis is a major 
risk factor for liver surgery, and even when liver resection is restricted to patients with 
well preserved liver function and in absence of portal hypertension, morbidity is high 
and perioperative mortality is 5 to 10 times higher than in non cirrhotic patients 4. 
Another contributing factor to poor outcome following major liver surgery is 
intraoperative blood loss typically occurring during parenchyma transsection 5-7. One 
strategy to prevent blood loss and the need for transfusion is inflow occlusion (i.e. 
Pringle maneuver). However, the interruption of blood flow to the liver induces 
ischemic injury which is a common cause of postoperative liver failure 8-10. Two 
strategies are available to minimize the negative impact of inflow occlusion, namely 
ischemic preconditioning and intermittent clamping 11 12. Intermittent clamping is the 
only strategy used in patients with liver cirrhosis, as no evidence is currently available 
showing protection from ischemic preconditioning in this population 13. Because 
intermittent clamping is associated with prolonged resection time and bleeding during 
each period of reperfusion, novel protective approaches are required in particular for 
livers with underlying diseases. 
An attractive protective approach is to subject the liver to a sub lethal stress, which was 
shown to trigger a variety of protective mechanisms 14, 15. This is the principle of 
ischemic preconditioning, where for example we found that the short period of ischemia 
causes a sub-lethal oxidative stress which induces potent antioxidant mechanisms 14. 
Exposure to low dose TNF-α, an established mediator of injury in the ischemic liver 16, 
was found to confer significant protection against prolonged periods of ischemia in a rat 
model. Fas and Fas ligand (FasL) are key mediators in the innate immune system 17 18 19, 
mediating injury in patients with viral and alcoholic hepatitis, and graft versus host 
disease 20 21. Therefore, both cell death cytokines, TNF-α and FasL, might be involved 
in the mechanism of I/R injury in the cirrhotic liver.  
This study was based on the hypothesis that “preconditioning” with FasL and TNF-α 
confer protection in the cirrhotic liver subjected to prolonged periods of ischemia. First, 
we developed a model of cirrhosis in mice mimicking the clinical situation, i.e., child A 
cirrhosis characterized by clear histological changes consistent with cirrhosis but well 
preserved liver function, and absence of portal hypertension. The next step was to 
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identify optimal doses of both death cytokines conferring protections followed by the 
search of the protective mechanisms triggered by each respective cytokine.          
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Materials and Methods 
Animals 
Male wild-type mice (C57BL6, Harlan, Netherlands) were used for all experiments 
(n=5, for each animal group). Animals were fed a standard laboratory diet with water 
and food ad libitum and were kept under constant environmental conditions. All 
experimental procedures were approved by the Swiss animal welfare authorities and 
performed in accordance with the institutional animal care guidelines. 
 
Induction of cirrhosis 
Cirrhosis was induced by carbon tetra chloride (CCl4) feeding by gavage. Equal 
volumes of CCl4 and soybean oil were mixed. 4ml/kg body weight was given 3 times 
per week for 6 weeks. For pathologic evaluation of cirrhosis Trichrome staining was 
conducted (Fig. 1 A). To evaluate severity of liver disease induced by CCl4, Child-
Turcotte-Pugh scoring was used. Levels of total bilirubin and albumin were measured 
using the serum multiple biochemical analyzer (Ektachem DTSCII, Johnson and 
Johnson Inc, Rochester, NY) for the scoring.  
  
Partial hepatic inflow occlusion 
A 70% segmental ischemia model was used as previously described 22 in normal or 
cirrhotic mice. Under isoflurane/O2 inhalation anaesthesia hepatic inflow to the median 
and left lobes was occluded by application of a micro-vascular clamp (Aesculap, San 
Francisco, CA). During ischemic periods, the abdomen was closed by a single running 
suture. Reperfusion was initiated by removing the clamp. The animal was allowed to 
wake up during reperfusion until sacrificed 1, 4, and 24 hours later.  
 
Death ligand preconditioning 
Mouse recombinant death ligand proteins (FasL and TNF-α) were purchased from R&D 
systems (Minneapolis, USA). To stimulate a protective effect against on an ischemic 
insult the proteins were injected into the peritoneum 40 minutes before hepatic blood 
flow occlusion. We selected FasL which is an ischemic injury non specific death ligand 
and TNF-α, an ischemic injury specific death ligand 16 as preconditioners.  
 
Serum transaminase levels 
Serum levels of AST or ALT were used as a marker of liver injury. Blood samples were 
obtained at each time point of reperfusion from the inferior vena cava. Blood cells were 
pelleted by centrifugation at 6000 rpm for 10 min at room temperature. Levels of 
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enzyme activities were measured using the serum multiple biochemical analyzer 
(Ektachem DTSCII, Johnson and Johnson Inc, Rochester, NY). 
 
Histological assessment 
Liver specimens were fixed in formalin. The tissues embedded in paraffin were 
sectioned and stained with hematoxylin and eosin. The necrotic area was visually 
identified by manual outlining and quantified by using an image analysis program 
(Saisam V.4.2.2, Microvision Instruments, Evry Cedex, France). The necrotic area was 
expressed as percentages of the whole surface area of the sections from ischemic lobes 
were analyzed.  
 
Double Immunostaining 
Tissue sections of paraffin embedded specimens were re-hydrated and incubated with 
two primary antibodies, Rat monoclonal anti mouse F4/80 antibody (BMA biomedicals) 
and Rabbit anti mouse HO-1 antibody (Stressgene). We followed the manufacturer’s 
instructions for blocking of non-specific binding and antigen retrieval (proteinase K for 
F4/80 and heating for HO-1). After color development of DAB using biotin-streptavidin 
for F4/80 (brown color), HO-1 immunostaining was performed by anti rabbit second 
antibody linked with alkaline phosphatase using fuchsin color development (bright red 
color). 
 
TUNEL stain 
The ApopTag kit (MP Biomedicals, Solon, OH, USA) was used to visualize nuclear 
DNA nicks by an immunoperoxidase detection of digoxigenin-labelled genomic DNA. 
The procedure was performed by manufacturer’s instruction. Briefly, liver sections were 
digested by protease K followed by inactivation of endogenous peroxidase with 3% 
H2O2 in methanol. The sections were incubated with residues of deoxigenin nucleotide 
and terminal deoxynucleotide transferase. The sections were then incubated with the 
antidigoxigenin antibody coupled with peroxidase. The cells with evidence of nuclear 
DNA fragmentation could be identified after incubating the sections with DAB and 
H2O2. 
 
Enzyme linked immunosorbent assay (ELISA) 
Serum samples were used to detect circulating TNF-α level by ELISA (Duo Set mouse 
TNF-α, R&D systems, Minneapolis, USA) following the manufacturer’s instructions. 
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Western blotting 
Mouse liver tissue was homogenized in Tris-based lysis buffer containing protease 
inhibitor cocktail (Roche Diagnostics GmbH, Mannheim, Germany). The protein 
concentration was determined using a Bradford protein assay (BioRad, Hercules, USA). 
Reduced SDS-PAGE was performed and samples were blotted onto a PVDF-membrane. 
Rabbit anti HO-1 (Stressgene), Rabbit anti-phosphorylated JNK (Cell signalling), and 
rabbit anti-FLIP and GAPDH (Abcam) polyclonal antibody was employed. Secondary 
antibody binding and detection were performed according to standard protocols with the 
ECL detection reagent (GE Healthcare Ltd, Buckinghamshire, UK). All results were 
measured by densitometry and expressed by relative expression to normal liver. 
 
HO-1 blocking experiment 
A specific HO-1 inhibitor, Zn-protoporphyrin (30µM/kg BW) (Frontier Scientific, Inc., 
Logan, Utah, USA), was administered by oral gavage 3 hours before hepatic inflow 
occlusion. The concentrated stock solution was protected from the light until used, and 
was diluted by saline just before gavage. 1 hour ischemia following 24 hours 
reperfusion was performed for this experiment. All other procedures were conducted as 
previously described.  
 
Kupffer cell inactivation 
Gadolinium chloride (10mg/kg BW) was injected into peritoneum of cirrhotic mice 24 
hours before ischemia in presence or absence of death ligand preconditioning. Mice 
were sacrificed 24 hours after reperfusion. 
 
Statistical analysis 
Data are presented as means ± SD. Groups were compared with the Student t-test for 
unpaired samples using Prism 4.0 (GraphPad Software, San Diego, CA, USA). A two-
sided p-value below 0.05 was considered to indicate as statistical significant. 
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Results 
Is the cirrhotic liver more susceptible to ischemic injury than the normal liver? 
We compared in a first set of experiments the effect of ischemia and reperfusion in 
normal and cirrhotic mice. The cirrhotic mice exhibit normal serum bilirubin and 
albumin levels, and no ascites, or no encephalopathy, representing Child-A cirrhosis. 
Serum transaminases levels and histology were used as endpoints. While after 1 hour of 
ischemia followed by 4 hours of reperfusion, serum AST and ALT levels were increased 
in both normal and cirrhotic animals, serum enzyme levels were significantly higher in 
cirrhotic animals (Fig. 1 D, E). Consistent with serum transaminase levels the extent of 
tissue injury determined by morphometry was also significantly higher in cirrhotic 
animals. Semi-quantitatively assessed tissue injury showed significantly more severe 
injury in cirrhotic animals (Fig. 1 C) than normal animals (Fig. 1 B) 4 hours after 
reperfusion (Fig. 1 F). These experiments show that cirrhosis adversely affects the 
response of the liver to ischemia and reperfusion.  
 
Is death ligand preconditioning protective against ischemic injury in cirrhotic 
livers? 
In this set of experiments we tested whether preconditioning with death ligands is 
protective against ischemia/reperfusion injury in the cirrhotic liver. In pilot studies FasL 
and TNF-α were injected at three different doses prior to ischemia. Four hours after 
reperfusion AST levels were significantly elevated in control animals, while animals 
injected with 1 ng/g body weight of TNF-α or FasL exhibited reduced markers of 
hepatic injury (Fig. 2 A, B). Subsequent preconditioning experiments were then 
performed with this dose. To evaluate the time course of injury, cirrhotic mice were 
pretreated with TNF-α, FasL or saline and studied 1, 4 or 24 hours after reperfusion. 
AST levels (Fig. 2 C) were dramatically lower in animals pretreated with either of the 
death ligands, particularly at 4 hours after reperfusion. Histological assessment 24 hours 
after reperfusion demonstrated a high degree of necrosis (48±12%) in saline treated 
animals (Supplementary figure A). The extent of necrosis was dramatically reduced (Fig. 
2 D) when FasL (22±12%) (Supplementary figure B) or TNF-α (16±8%) 
(Supplementary figure 1 C) preconditioning was applied before ischemia. To further 
confirm whether TNF-α and FasL would protect the liver from ischemic injury, a 
survival study was performed. While saline injected control animals had a 20% survival 
rate, 60% survived after TNF-α treatment and 100% after FasL application, supporting 
our conclusion that these cytokines are protective at low doses (Fig. 2E). Tissue damage 
was characterized by apoptosis, extensive necrosis, and infiltration of inflammatory 
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cells 24 hours after reperfusion.  
 
Does death ligand preconditioning protect the cirrhotic liver from apoptotic cell 
death? 
Apoptosis is a common feature of liver injury caused by ischemic insult. To investigate 
the protective mechanisms we assessed apoptotic markers, e.g. TUNEL staining, 
enzymatic assay of caspase 3, serum level of TNF-α by ELISA, detection of 
phosphorylated Jun amino-terminal kinase (pJNK), FLICE (caspase 8) inhibitory 
protein (FLIP) by western blotting after 4 hours of reperfusion. TUNEL staining of 
cirrhotic livers without ischemic injury revealed approx. 2% of cells with apoptotic 
nuclei. In contrast 4 hours after an ischemic insult, almost 35% of the nuclei appeared to 
be apoptotic (Fig. 3 A, Supplementary figure D). Pretreatment with death ligands caused 
a significant reduction in TUNEL-positive nuclei, suggesting that both FasL and TNF-α 
preconditioning induced a defence against apoptosis (Fig. 3 A, Supplementary figure E, 
F). This conclusion was supported by the assessment of active caspase 3. In saline 
treated animals, activity of caspase 3 was significantly increased compared to either 
sham operated or preconditioned animals (Fig. 3 B). To further study entry into 
apoptosis, the presence of serum TNF-α, pJNK, and FLIP was determined. Activation of 
JNK by TNF-α and reactive oxygen species (ROS) after ischemia following reperfusion 
leads to hepatocyte apoptosis and degradation of the anti-apoptotic molecule FLIP 23, 24. 
Circulating TNF-α was low in sham-operated animals. In saline injected animals, TNF-
α was increased almost 10-fold 4 hours after reperfusion. Again, both death ligands 
effectively reduced the secretion of TNF-α 4 hours after pre-treatment (Fig. 3 C). 
Activation of JNK was associated with turnover of FLIP. Activated JNK was 
significantly increased in saline treated animals compared to preconditioned groups (Fig. 
3 D, F). After 4 hours of reperfusion the amount of FLIP was significantly reduced in 
saline treated group (Fig. 3 E, F).  
 
Does death ligand preconditioning induce protective molecules against ischemic 
injury in the cirrhotic liver? 
Preconditioning with TNF-α has been shown to reduce tissue injury subsequent to 90 
minutes ischemia and reperfusion in healthy female mice through MAPkinases and 
Nfkb activation 25. To identify the mechanism by which death ligand preconditioning 
induces cytoprotection we evaluated a number of proteins, which are known to be 
protective in an ischemic insult, since FasL and TNF-α preconditioning in cirrhotic liver 
appear to mediate their protection through mechanisms different from the healthy liver. 
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Proteins, such as HSP-70, Bcl-2 and HO-1 are reportedly induced during ischemia and 
provide protection in subsequent reperfusion 26, 27. To investigate the effect of 
preconditioning, animals were untreated (normal), saline (sham), TNF-α, and FasL 
injected. After 40 minutes, corresponding to the preconditioning time prior to ischemia, 
liver tissue was directly harvested and processed for analysis. 
While neither HSP-70 nor Bcl2 disclosed any changes (data not shown), HO-1 was 
induced, respectively by a factor of 2 (FasL) and 2.5 (TNF-α) in tissue homogenates 
(Fig. 4 A). Although, the induction was not very strong, we further investigated the 
distribution of HO-1 in the preconditioned livers. In comparison to normal or sham 
animals, FasL treated or TNF-α treated animals exhibited an increased number of cells 
expressing HO-1 in F4/80 positive cells, presumably Kupffer cells (Fig. 4 B). A 
histomorphometric analysis demonstrated a >3-fold increase in the number of HO-1 and 
F4/80 double positive cells (Fig. 4 C). Other leukocyte infiltrates, i.e. neutrophilic 
granulocytes assessed by myeloperoxidase staining, were similar in the preconditioned 
and the saline control livers. 
 
Does HO-1 play a central role in death ligand preconditioning? 
The previous experiment pointed out to a protective role of HO-1. To further 
substantiate this hypothesis, we treated the cirrhotic animals with a specific inhibitor of 
HO-1, Zn-protoporphyrin (ZnPP). 3 hours later all animals were pretreated with saline 
(sham), FasL or TNF-α for 40 min. Following ischemia for 1 hour livers were 
reperfused for 24 hours. Markers of injury, i.e.; AST (Fig. 5 A) and necrosis (Fig. 5 B), 
demonstrated considerable liver damage in saline injected cirrhotic animals. The 
inhibitor ZnPP did not have any effect in cirrhotic control animals. As shown before, 
FasL or TNF-α pre-treatment of cirrhotic animals strongly reduced tissue injury after 
reperfusion. However, the effect of FasL or TNF-α was completely abolished by HO-1 
inhibitor treatment (Fig. 5 A, B). Therefore, we conclude that the induction of HO-1 is a 
central mechanism of cytoprotection in the cirrhotic liver.  
 
Are Kupffer cells involved in the response of death ligand preconditioning? 
In this experiment we investigated whether Kupffer cells are responsible for the 
protective effect by TNF-α preconditioning. Therefore we inactivated Kupffer cells by 
GdCl3 (10mg/kg BW in saline), given through i.p injection 24 hours before ischemia. 
After 60 minutes of ischemia and 24 hours of reperfusion, serum AST levels (Fig. 6 A) 
and tissue injury (Fig. 6 B) reached similar levels as saline treated control animals. To 
demonstrate that TNF-α is acting through Kupffer cells, cirrhotic animals were injected 
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with TNF-α alone or in combination with GdCl3. TNF-α preconditioning, as expected 
protected liver from ischemic insult. When Kupffer cells were silenced by GdCl3, TNF-
α was ineffective. This suggest that TNF-α mediates its effect through a Kupffer cell 
dependent pathway. 
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Discussion 
Preconditioning of both FasL and TNF-α given shortly prior to an ischemic injury 
significantly ameliorate injury subsequent to reperfusion with dramatic reduction of 
apoptotic cell death and subsequent necrosis. We further identify HO-1 as protective 
mechanism downstream of death ligand preconditioning. As HO-1 was located mostly 
in the macrophages in the liver (Kupffer cells) and Kupffer cell inhibition led to a 
reversal of the protective effects of FasL and TNF-α, we concluded that death ligand 
preconditioning confer dramatic protection in the cirrhotic liver though a HO-1–Kupffer 
cell dependent pathway.  
 
Clinical relevance and model  
To reduce the postoperative morbidity and mortality, several procedures have been 
proposed that protect the liver. While both procedures of ischemic preconditioning and 
intermittent clamping 11 are successful in many patients, recent evidence has shown that 
both procedures are not effective enough in a subset of patients with complex disease 
and the elderly 28. Therefore, alternative procedures are required to induce protection 
with pharmacological preconditioning being the most attractive because it is not 
invasive and can be easily given prior to surgery 26. The novel finding in this study is 
the protective effects of FasL and TNF-α given prior to a prolonged ischemic insult. 
Both mediators induce cell death at high doses but at low doses they can activate a 
number of cell types involved in liver injury, including Kupffer and endothelial cells.  
An additional formidable challenge to improve surgery in patients with cirrhosis is the 
availability of suitable experimental models where mechanism of injury can be 
investigated. The mouse model of cirrhosis is an accepted model of extensive 
parenchymal destruction with bridging fibrosis 29. Parenchymal destruction is induced 
by chronic administration of a toxic substance i.e. CCl4 30. This toxic model is widely 
used, yet it has its limits and does not completely reiterate the pathophysiological 
changes seen in human cirrhosis. The mouse liver appears to constantly regenerate and 
it has been observed that the mouse liver is able to completely reverse ‘cirrhosis’ when 
CCl4–feeding is terminated. Thus, in the strictest sense of the definition of cirrhosis i.e. 
irreversible fibrosis, the mouse liver is imperfect. Nevertheless, the maintenance of 
extensive fibrosis in the liver is paramount to the current efforts to understand and 
improve human liver cirrhosis.  
 
Preconditioning effects in the mouse liver 
In the current experiments we used 40 minutes of preconditioning prior to surgery. Pilot 
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experiments with a dose response curve for both death ligands identified a dose of 1 
ng/g body weight. A significant improvement could be observed for all parameters 
tested. The injury, as exemplified by transaminase levels was transient; however, the 
ensuing necrosis was extensive 24 hrs after reperfusion. At 4 hours after reperfusion 
apoptosis was significantly improved. From the rapid conversion of apoptosis to 
necrosis in this model, we assume that entry into apoptosis at 4 hours after reperfusion 
might not result in a full execution of programmed cell death in these animals. 
Presumably, a significant number of cells will turn necrotic, particularly in those 
animals not protected by preconditioning. This process, termed “apo-necrosis” leads to 
inflammation and, when considering the extent of necrosis observed in the cirrhotic 
liver (almost 50%), potentially to a complete loss of organ function 31. 
FasL and TNF-α induce a cell death in many cell types. However, they might stimulate 
cellular pathways without detectable organ injury in a certain dose. We could not find 
injury markers assessed by TUNEL, HE, caspase3 and 8 western blotting (data not 
shown). We had expected that death ligand preconditioning induces MAPkinase 
activation, including p38, Erk, and JNK as shown by Teoh at al. in normal mice 25. It is 
not clear if HO-1 positive macrophages are recruited or derived from the liver. 
The devastating impact of ischemia and reperfusion on postoperative injury with 
extensive necrosis was almost completely prevented with a single dose of death ligand. 
This observation supports the concept of pharmacological preconditioning. While the 
application of TNF-α or FasL might be difficult in clinical practice at this moment, the 
potential to apply a single dose 40 minutes prior to surgery paves the way to safe drugs 
applied in a similar fashion. In our opinion, the crucial point will be to target a 
protective reaction e.g. in Kupffer cells. Whether this will be with modified ‘blunted’ 
death ligands or other activators of Kupffer cells are not clear. The beneficial effects, 
combined with ease of handling, might provide novel attractive strategies in the 
cirrhotic population, who are particularly prone to develop liver failure after surgery. 
We identified HO-1 and Kupffer cells as a downstream protective target of both death 
ligands in cirrhotic livers. HO-1 is a well established hepatoprotective molecule which 
has an anti-oxidative, anti-inflammatory, vaso-relaxation, anti-apoptotic effect 32-35. 
Accumulating data about HO-1 production in the liver indicate that Kupffer cells are a 
major source of HO-1 36. To use the benefit of this molecule some applicable methods 
have been suggested. Yutamura at al. showed induction of HO-1 by giving hemin, a 
potent HO-1 inducer in normal rat liver graft 37. But it is unclear whether it will induce 
Kupffer cell specific HO-1 in cirrhotic liver.  
In summary, we show that a single dose of TNF-α or FasL strongly protects the cirrhotic 
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liver against ischemia and reperfusion injury We further provided strong evidence that 
this protective effects are mediated by HO-1 located in Kupffer cells. A single injection 
of drugs targeting HO-1 in Kupffer cells might provide an attractive alternative therapy 
to prevent loss of tissue integrity and improve morbidity in cirrhotic patients undergoing 
liver surgery. 
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Figure Legends 
 
Figure 1. Comparison of liver injury in normal and cirrhotic animals after 4 hours of 
reperfusion. Cirrhotic change is shown by Trichrome staining after 6 weeks of CCl4 
feeding (A). Normal and cirrhotic mice were subjected to 1 hour ischemia following 4 
hours reperfusion, serum transaminases (D, E) and histology (B, C, F) were assessed. 
Necrosis determined by histomorphometry is expressed as % necrotic area relative to 
total area. H/E staining used for histomorphometric evaluation showed pale hepatocytes, 
condensed nuclei, and heavy congestion after 4 hours of reperfusion in normal (B) and 
cirrhotic (C) liver (50X magnification). The differences of tissue injury markers 
between normal and cirrhotic animals were statistically significant. * T-test P<0.05  
 
Figure 2. Dose response curve of death ligand preconditioning in cirrhotic livers. The 
most protective concentrations of FasL and TNF-α were found by pilot studies in 
cirrhotic animals. Serum AST levels and necrotic area were taken to evaluate the effects 
of death ligand preconditioning. Death ligands applied at 1ng/g body weight showed 
significantly less serum AST levels than either control and other groups tested with 
higher concentration of death ligands (A, B). Time course AST levels after 1, 4, and 24 
hours of reperfusion (C). Histomorphometric evaluation of necrotic area (D). * T-test 
P<0.05. (E) Survival rate of cirrhotic mice after 60 minutes of 70% ischemia. Mice 
were preconditioned by FasL, TNF-α or saline injection. After ischemia, the non-
ischemic lobes were removed and the mice were allowed to wake up. The survival 
experiment was terminated after 7 days.  
 
 
Figure 3. Effect of death ligand preconditioning on apoptosis. TUNEL staining was used 
to indicate areas of apoptosis (A). Activity of caspase3, the executer caspase, by 
enzymatic assay (B). Determination of TNF-α secretion in serum of mice 4 hours after 
reperfusion (C). Phosphorylation of JNK (D, F), and amount of FLIP is presented by 
western blotting (E, F). Sham: cirrhotic mouse undergoing a sham operation. Control: 
cirrhotic mouse with ischemia for 1 hour/4 hours reperfusion. FasL/TNF-α injected with 
death ligand 40 min. prior to ischemia. * T-test P<0.05 
 
Figure 4. Death ligand preconditioning induces HO-1 in non-parenchymal cells before 
ischemia. HO-1 expression was determined by Western blotting, and 
immunohistochemistry. Western blotting of tissue extract for HO-1 (A) was performed 
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after 40 min. of preconditioning in normal and cirrhotic mice. Co-expression of F4/80 
and HO-1 in the non-parenchymal cells by death ligand preconditioning (B). Examples 
of individual cells which are either F4/80 positive (B-1, brown colour), HO-1 positive 
(B-2, bright red colour), F4/80 and HO-1 double positive (B-3) are shown separately. 
Morphometric determination of F4/80 and HO-1 double positive cells (C). The numbers 
of double positive cells were highly increased by death ligand preconditioning. * T-test 
P<0.05 
 
Figure 5. Inhibition of HO-1 reverses ischemic injury in cirrhotic liver. The effect of 
HO-1 was inhibited by Zn-protoporphyrin (PP) administration by gavage. The 
inhibitory capacity was assessed by serum AST and histomorphometry of necrotic area 
after 24 hours reperfusion. Serum AST levels of Zn-PP+death ligand groups showed 
significantly higher levels compared to the death ligand preconditioned group (A). 
Consistent with AST data, the necrotic area was significantly more pronounced in Zn-
PP+death ligand groups than in control group (B). * T-test P<0.05 
 
Figure 6. Protective effect of death ligand preconditioning is Kupffer cell dependent. 
GdCl3, an inhibitor of Kupffer cell, injected 24 hours prior to ischemia reversed 
ischemic injury in TNF-α treated animal. Serum AST and necrotic area were measured 
to demonstrate the inhibitory effect of GdCl3 against Kupffer cell activity after 24 hours 
of reperfusion. GdCl3 reversed serum AST level similar to the control group (A). 
Similarly, the necrotic area was comparable to the control groups when GdCl3 and TNF-
α were applied. * T-test P<0.05  
 
Supplementary figure. Histological observation after 24 hours of reperfusion presented 
by haematoxylin-eosin staining and TdT dUTP nick end labelling (TUNEL). 
Representative liver sections 24 hours after reperfusion. H/E stained sections of 
cirrhotic livers with necrosis and inflammation. Control (A), FasL preconditioned (B), 
and TNF-α preconditioned (C) mice. Magnifications are 50X. Representative TUNEL 
stained tissue sections of control (D), FasL (E), and TNF-α preconditioned (F) mice 4 
hours after reperfusion.  
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to combine adult and paediatric practice (eg,
the chapters on assessment and on intestinal
failure-associated liver disease). I would not
be so unkind as to describe it from the
perspective of the curate faced with the
dodgy egg, but I did find it somewhat
unsatisfactory. It is good as it prompts both
groups of specialists to consider problems
more particular to the other, but these
chapters seem to lose focus in the process.
I was disappointed to find no mention of the
random urine sodium in assessment of the
intestinal failure patient—in my view a
hugely helpful simple investigation—but
perhaps its absence is symptomatic of its
neglect in the literature as a whole.
An important portion of the book revolves
around intestinal transplantation (16 of the
42 chapters), and there are many gems
therein. It is helpful to have the surgical
approaches summarised, but these are of
most practical relevance to those in trans-
plant centres, and I think most potential
readers will be more concerned with the
prior strategies on indications and referral,
and with the postoperative aspects in
patients who may be seen once they are
released from hyperspecialist care.
Accordingly I was disappointed with the
chapter on long-term management as the
opportunity to provide a hit-list of things
that must and must not be done has been
missed. This screams out for a secure
algorithm for the non-specialist centre faced
with a sick (or indeed not so sick) transplant
patient. Finally there are no transplant out-
come data more recent than 2005–6, which is
a shame for such a rapidly moving field; I had
hoped that Professor Grant might have given
a sneak preview of more recent results.
On balance I am very positive about the
book, consider it very good value for money
and would strongly recommend it to all units
dealing with intestinal failure. Some oppor-
tunities have been missed, and I am sure these
will be dealt with in the future editions that
are likely to emerge. It scores over the
Nightingale book in its handling of transplan-
tation, but this is mainly the consequence of
the 7 years that separate the two volumes.
Personally I am pleased to have both!
Alastair Forbes
Correspondence to: Professor A Forbes, Department of
Gastroenterology and Nutrition, University College Hospital,
235 Euston Road, London NW1 2BU, UK; a.forbes@ucl.ac.uk
Endoscopy in a new light…
Edited by J Cohen. Published by Blackwell, Oxford, 2007,
pp 317, hardcover with DVD, £110. ISBN 9781405158862
Narrow band imaging (NBI) comes as
standard with the latest version of the
hardware sold by the UK’s most popular
supplier of endoscopy equipment, but how
many UK gastroenterologists know the
theory of the new modality, how to use it,
the appearances of even common lesions and
the potential benefits for patients? This
book attempts to bring the experience of
the (mostly Japanese) front runners in NBI
to a more general audience.
NBI uses restricted parts of the spectrum
of white light to enhance the vessel pattern
and superficial detail of mucosal lesions,
allowing the diagnosis of early lesions such
as cancers and dysplasia, so poor in current
UK endoscopic practice. It is easy to use in
narrow tubular organs such as the oesopha-
gus and colon where light intensity is
relatively high; light levels are lower in the
more capacious stomach, reducing the value
of NBI as a screening tool, though it still
appears to be of value in detailed study of
lesions first suspected by white light endo-
scopy. It is easy to deploy at the touch of a
button, making it more practical than
chromoendoscopy. There is a lot to learn
about interpretation of the images where
haemoglobin is shown in brown or green
depending on the depth and size of the
containing vessel, and the importance of the
microvascular pattern. The common arte-
facts, due to poor bowel preparation for
example where faeces is rendered as red, take
some adjustment in the brain of the
endoscopist. There are also more related
acronyms and more Japanese classifications
to take on!
The utility of NBI is not yet well
supported by peer-reviewed publications,
and as this book makes clear, it is comple-
mentary to a variety of other modalities
including high-resolution endoscopy (HRE),
magnification and chromoendoscopy which
are not yet routine in UK endoscopy units.
The chapters explaining the basis of NBI
and its potential applications are in quite good
English, but some parts have not translated
well from the original Japanese articles. The
book contains a large series of good-quality
endoscopic photos which could be better
arranged, however. The illustrations with
each chapter are printed at the end of the
chapters, rather than integrated in the text
where they would be easier to relate. The
atlas in the second half of the book presents
white light, NBI and magnification and
chromoendoscopy images of lesions, but not
always on the same page which is slightly
irritating. The text and images also come on
an included searchable DVD containing good-
quality still images from the book and 55
video clips. The perfection of the Japanese
clips is remarkable and the videos are very
helpful in understanding the NBI appear-
ances, though a number of the sequences are
irrelevant to the subject of the book and seem
to have been included as ‘‘stocking fillers’’.
Endoscopy now has to compete with
other non-invasive imaging techniques.
NBI, HRE and other new intraluminal
imaging modalities are likely to give endo-
scopy a sensitivity unmatched by any other
technique, and combined with its therapeu-
tic potential will contribute to the develop-
ment and survival of endoscopy. The
benefits to patients of this increased sensi-
tivity will need to be shown, but serious
endoscopists will want to assimilate the
contents of this publication, recognising
that the study of NBI has much potential.
Peter D Fairclough
Correspondence to: Dr P Fairclough, Endoscopy Unit, The
Royal London Hospital, London E1 1BB, UK; peter.f@
pobox.com
CORRECTIONS
doi:10.1136/gut.2007.137703corr1
J-H Jang, W Moritz, R Graf, et al.
Preconditioning with death ligands FasL
and TNF-a protects the cirrhotic mouse liver
against ischaemic injury. Gut 2008;57:492–9.
The authors would like to add one further
source of funding: EMDO stiftung, Zurich,
Switzerland (to J-H Jang and P-A Clavien).
doi:10.1136/gut.2007.129296corr1
Y Motomura, J-E Ghia, H Wang, et al.
Enterochromaffin cell and 5-hydroxytrypta-
mine responses to the same infectious agent
differ in Th1 and Th2 dominant environ-
ments. Gut 2008;57:475–81. There is an
error in the key for figure 5: solid bars
represent SCID+ Th2 and open bars repre-
sent SCID+ Th1.
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